Previous 10 | Next 10 |
Previous Data from Investigator-Initiated Phase 1/2 Trial Show Encouraging Response Rates, Durability and a Favorable Safety Profile Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib Verastem to Seek FDA Accelerated Approval, Pe...
Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC)...
SCWorx (WORX) +100%.Professional Diversity Network (IPDN) +25%.Apex Technology Acquisition (APXT) +20%.Genfit SA (GNFT) +18%.Xinyuan Real Estate (XIN) +17% on Q3 results.Rhythm Pharmaceuticals (RYTM) +16% as FDA OKs it's Imcivree for weight management in obese patients.Shi...
Are These Biotech Penny Stocks On Your Watch List Right Now? While the traders digest the latest news in the stock market today, penny stocks remain a focal point. These cheap stocks are some of the most exciting especially during times where volatility might be lacking in the broad...
Verastem (VSTM): Q3 GAAP EPS of $0.08 beats by $0.04.Revenue of $78.65M (+773.9% Y/Y) beats by $52.18M (includes sale of COPIKTRA (duvelisib)).Cash, Cash Equivalents and Investments of $205.7M.Press Release For further details see: Verastem EPS beats by $0.04, beats on revenue
Announced Positive Updated Data from Ongoing Investigator-Initiated Phase 1/2 FRAME Study Evaluating VS-6766 and Defactinib Combination in Patients with Low-Grade Serous Ovarian Cancer On Track to Commence Company-Sponsored Phase 2 Registration-Directed Trials by Year-End 2020...
Biotech Penny Stocks to Watch In November 2020 Biotech penny stocks have been making some big headway in the market in the past six months. Following the advent of Covid, many investors began to hedge bets on biotech stocks for the future. While some stocks that are dealing with...
Universal Security Instruments (UUU) +87%.Cellect Biotechnology (APOP) +36%.Pinterest (PINS) +31% on Q3 results.Inphi Corporation (IPHI) +27% as the company will be acquired by Marvell in a cash and stock transaction.Xtant Medical Holdings (XTNT) +22% on Q3 resul...
Investigator-Initiated Phase 1 Study is First to Evaluate a Dual RAF/MEK Inhibitor Using Innovative Intermittent Dosing Schedules in Patients Harboring RAS/RAF Pathway Mutations Study Finds VS-6766 Regimen is Tolerable and Shows Antitumor Activity in Recommended Phase 2 Single...
Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRAS Mutant NSCLC Expected to Commence by Year End 2020 Verastem...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...